Literature DB >> 21775916

Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.

Takahiro Einama1, Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Hiromi Kanno, Kenta Takahashi, Ayami Sasaki, Munenori Tahara, Kuniaki Okada, Shunji Muraoka, Toshiya Kamiyama, Yoshihiro Matsuno, Michitaka Ozaki, Satoru Todo.   

Abstract

OBJECTIVES: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma.
METHODS: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise.
RESULTS: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062).
CONCLUSIONS: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775916     DOI: 10.1097/MPA.0b013e318221bed8

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  42 in total

1.  Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Authors:  Elad Sharon; Jingli Zhang; Kevin Hollevoet; Seth M Steinberg; Ira Pastan; Masanori Onda; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan
Journal:  Clin Chem Lab Med       Date:  2012-04       Impact factor: 3.694

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 3.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

Review 4.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

5.  Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.

Authors:  Weikang Liu; Bingjun Tang; Feng Wang; Chang Qu; Hao Hu; Yan Zhuang; Hongqiao Gao; Xuehai Xie; Xiaodong Tian; Yinmo Yang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.

Authors:  Mirte M Streppel; Audrey Vincent; Radha Mukherjee; Nathaniel R Campbell; Shih-Hsun Chen; Konstantinos Konstantopoulos; Michael G Goggins; Isabelle Van Seuningen; Anirban Maitra; Elizabeth A Montgomery
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

Review 7.  Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Authors:  Takahiro Einama; Futoshi Kawamata; Hirofumi Kamachi; Hiroshi Nishihara; Shigenori Homma; Fumihiko Matsuzawa; Tatsuzo Mizukami; Yuji Konishi; Munenori Tahara; Toshiya Kamiyama; Okio Hino; Akinobu Taketomi; Satoru Todo
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

Review 8.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

9.  Mesothelin expression and survival outcomes in triple receptor negative breast cancer.

Authors:  Napa Parinyanitikul; George R Blumenschein; Yun Wu; Xiudong Lei; Mariana Chavez-Macgregor; Melody Smart; Ana Maria Gonzalez-Angulo
Journal:  Clin Breast Cancer       Date:  2013-06-27       Impact factor: 3.225

10.  Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.

Authors:  Jose M Pimiento; Ashley H Davis-Yadley; Richard D Kim; Dung-Tsa Chen; Edward A Eikman; Claudia G Berman; Mokenge P Malafa
Journal:  Clin Nucl Med       Date:  2016-03       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.